Cart
sales@molnova.com
Home - Products - Angiogenesis - VEGFR - Bevacizumab

Bevacizumab

CAS No. 216974-75-3

Bevacizumab( —— )

Catalog No. M22136 CAS No. 216974-75-3

Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 357 In Stock
10MG 482 In Stock
25MG 779 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Bevacizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
  • Description
    Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
  • In Vitro
    Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.
  • In Vivo
    It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p?
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    216974-75-3
  • Formula Weight
    149 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Fruquintinib

    A potent and highly selective small molecule inhibitor of VEGFR1/2/3 with IC50 of 33/3/5/0.5 nM, respectively.

  • BIBF 1202

    BIBF 1202 is a VEGFR2 kinase inhibitor (IC50 = 62 nM).

  • Tyrosine kinase-IN-1

    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor(KDR Flt-1 FGFR1 and PDGFRα with IC50s of 4nM 20nM 4nM 2 nM respectively).

Sign In Join Free